CURE Pharmaceutical Gets Patents for Cannabis Extraction

Cannabis Investing News

CURE Pharmaceutical announced the acquisition of two new patents for the extraction and purification of cannabis plant material.

CURE Pharmaceutical (OTC:CURR) announced the acquisition of two new patents for the extraction and purification of cannabis plant material.

As quoted in the press release:

“The endocannabinoid system is a powerful pathway to treat many diseases and illness, and these patents will allow us to implement accurate and optimal dosing for treatments that would target this system,” said Rob Davidson, CEO of CURE Pharmaceutical. “We have only seen a glimpse of the potential of cannabinoids, which we are unlocking with our proprietary delivery technology.”

The patents will be key to reproducing and commercializing the research findings from the Technion – Israel Institute of Technology, a public research university in Haifa, Israel where CURE is sponsoring research. The current research at Technion is testing fractionated molecular components from the cannabis plant against various cancer types in vitro and in preclinical models.

The two issued U.S. patents No. 9,044,390 and 9,186,386 cover the extraction and fractioning of bioactive cannabinoid molecules from the cannabis plant, allowing the integration of these molecules into a dosage form, such as CUREfilm™, the most advanced oral thin film on the market today.

Click here to read the full press release.

Source: globenewswire.com

The Conversation (0)
×